Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Relapsed or Refractory Hematologic Malignancies
Interventions
DRUG

Trichostatin A

Intravenous Infusion

Trial Locations (11)

20007

WITHDRAWN

Vanda Investigational Site, Washington D.C.

47905

COMPLETED

Vanda Investigational Site, Lafayette

98109

COMPLETED

Vanda Investigational Site, Seattle

07601

WITHDRAWN

Vanda Investigational Site, Hackensack

Unknown

RECRUITING

Vanda Investigational Site, Biała Podlaska

RECRUITING

Vanda Investigational Site, Katowice

RECRUITING

Vanda Investigational Site, Krakow

RECRUITING

Vanda Investigational Site, Opole

RECRUITING

Vanda Investigational Site, Skorzewo

RECRUITING

Vanda Investigational Site, Warsaw

RECRUITING

Vanda Investigational Site, Wroclaw

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY